Last reviewed · How we verify
DA-6034
DA-6034 is a selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ) that enhances lipid metabolism and reduces inflammation.
DA-6034 is a selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ) that enhances lipid metabolism and reduces inflammation. Used for Dyslipidemia, Metabolic syndrome.
At a glance
| Generic name | DA-6034 |
|---|---|
| Also known as | Placebo |
| Sponsor | Dong-A ST Co., Ltd. |
| Drug class | PPARδ agonist |
| Target | PPARδ (peroxisome proliferator-activated receptor delta) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Metabolic |
| Phase | Phase 3 |
Mechanism of action
DA-6034 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and glucose homeostasis. By selectively targeting PPARδ, the drug promotes beneficial metabolic changes and anti-inflammatory effects, potentially improving dyslipidemia and metabolic dysfunction. This mechanism differs from pan-PPAR agonists by offering more selective tissue effects with potentially improved safety.
Approved indications
- Dyslipidemia
- Metabolic syndrome
Common side effects
- Muscle pain or myalgia
- Gastrointestinal disturbances
- Elevated liver enzymes
Key clinical trials
- Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers (PHASE1)
- Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome (PHASE2)
- A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DA-6034 CI brief — competitive landscape report
- DA-6034 updates RSS · CI watch RSS
- Dong-A ST Co., Ltd. portfolio CI